The global Transcatheter Mitral Valve Implantation Market was valued at USD 1.82 billion in 2019 and is expected to reach USD 4.67 billion by 2027, at a CAGR of 14.4%, according to Emergen Research. The rising prevalence of mitral valve diseases, increasing pipeline devices, and an ageing population with heart disease are all driving the growth prospects of the Transcatheter Mitral Valve Implantation (repair and replacement) market in the forecast period. Mitral regurgitation (MR) is the most common valve disorder, affecting over 4 million people in the United States. In the United States, approximately 250,000 cases of mitral regurgitation are recorded each year, with approximately 50,000 patients deciding to undergo recommended surgery.
The executive summary of the Transcatheter Mitral Valve Replacement research report provides a brief overview of the market. It identifies the key segments and players who will shape the market over the next few years. The executive summary presents an objective view of the market. The research report on the Transcatheter Mitral Valve Replacement market focuses on Engines in the following chapters. He discusses how demographic shifts will affect demand and supply in the Transcatheter Mitral Valve Replacement market. It focuses on regulatory changes that are expected to alter the outlook. Furthermore, the researchers discussed the actual source of the request in order to determine its nature.
The report discusses key market developments as well as organic and inorganic growth strategies in the Transcatheter Heart Valve Replacement and Repair market. Various businesses are focusing on organic growth strategies such as product launches, product approvals, and other things like patents and events. Acquisitions and partnerships and collaborations were observed as inorganic growth strategies in the market. These activities have paved the way for market participants to expand their business and customer base. With the rising demand for Transcatheter Heart Valve Replacement and Repair in the global market, market players in the Transcatheter Heart Valve Replacement and Repair market are expected to have lucrative growth opportunities in the future.
Further key findings from the report suggest
In order to develop functional (secondary) mitral regurgitation, MitraClip’s suggestions to address secondary MR were expanded and approved by the US Food and Drug Administration in March 2019. (FDA). This can be given to patients who have structural changes in their hearts (such as enlargement due to heart failure)
Mechanical valves are expected to dominate the industry with a market share of nearly 58.3% because they last for approximately 25 years after implant/surgery.
Mitral Valve Stenosis dominates the market in 2019, with a market share of approximately 44.1%. However, the Mitral Valve Regurgitation segment in the applications outlook grew at the fastest rate of approximately 14.1% due to an increase in mitral regurgitation conditions and the expansion of potential techniques for successful surgeries.
Abbott Laboratories, HLT Medical, Neovasc, Edward Lifesciences, Biotronik Private Limited, LivaNova, Colibri Heart Valve, Medtronic, NeoChord, MValve Technologies, Transcatheter Technologies GmbH, and Venus Medtech are among the key market players profiled in this industry analysis.
For the purpose of this study, Emergen Research have segmented Transcatheter Mitral Valve Implantation Market on the basis of product, application, end use and region:
Product Outlook (Revenue in Million USD; 2017–2027)
- Mechanical Valves
- Bioprosthetic Tissue (Biological) Valves
Application Outlook (Revenue in Million USD; 2017–2027)
- Mitral Valve Stenosis
- Mitral Valve Prolapse
- Mitral Valve Regurgitation
End Use Outlook (Revenue in Million USD; 2017–2027)
- Ambulatory Surgical Centers
- Diagnostic Centers
Regional Outlook (Revenue in Million USD; 2017–2027)
- North America
- Rest of the Europe
- Asia Pacific
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America